YARON DANIELY, Ph.D., M.B.A.

62 Hey BeIyar Street, Tel-Aviv, Israel 62198 Tel (+9723) 6021214, Cell (+97252) 8833383, Yaron@alcobra-pharma.com

EDUCATION

Executive M.B.A., September 2002 - December 2004
Graduated Cum Laude
Technion, Israel Institute of Technology, Haifa, Israel
High Tech Management and Business Strategy Track

Postdoctoral Fellow, October 2000 - June 2003
Department of Molecular Cell Biology
The Weizmann Institute for Science, Rehovot, Israel
American Cancer Society Postdoctoral Fellowship '01-'04
Israel Cancer Research Fund Postdoctoral Fellow '01-'03
Research Area: The role of the newly discovered gene *p63*, a homologue of the tumor suppressor protein p53, in oncogenesis, development and apoptosis.

NIH Visiting Fellow, October 2001 – February 2002
Cell Biology Section, national Institute of Environmental Health Sciences
National Institute of Health, Research Triangle Park, NC 27709
Research Area: Keratinocyte differentiation and the DNA damage response.

Ph.D. January 1999 - October 2000
M.Sc. August 1996 - January 1999
Sackler Institute of Graduate Biomedical Sciences
New York University School of Medicine, New York, New York
Major: Basic Biomedical Sciences, Cellular and Molecular Biology
NIH Research Training Grant Recipient '97-'00
Honorable Mention, Predoctoral Fellowship Competition, NSF '97
Thesis Title: DNA replication inhibition and nucleolin relocalization following cell stress.

B.Sc. August 1993 - April 1996
Graduated Cum Laude
Florida International University, Miami, Florida
Major: Biological Sciences
Faculty Scholars and Florida Merit Scholars Fellowships '93 - '96
Member of Honor Society and Faculty Scholars Group
Dean's List for Each Semester
Honors Thesis Title: Computer-based modeling for the prediction of protein folding.

PROFESSIONAL EXPERIENCE

CEO, Alcobra Ltd. (NASDAQ:ADHD)

- A pubic, advanced clinical-stage pharmaceutical company in the area of CNS diseases
- Lead the company's Initial Public Offering (IPO) on NASDAQ, raising $63M
- Lead the company through strategic investment by large Pharmaceutical company

June 2010 – present

President & CEO, NanoCyte, Inc.

- A private clinical-stage start-up in the area of Transdermal Drug Delivery
- Provide cross-functional direction for R&D, clinical, financial, and commercial activities
- Oversee company's regulatory submissions in USA, Israel, EU, and India
- Supervise re-design of manufacturing process to commercial specifications and capacity
- Initiate and maintain multiple international strategic alliances with large- and medium-size companies and academic groups

November 2007 – June 2010

General Manager, Gamida Cell-Teva Joint Venture Ltd. (StemEx®)

- Manage multi-national, multi-center Phase III study in US, Europe and Israel; Manage all committee personnel and activities in clinical, marketing, development, and regulatory aspects of StemEx® registration study; report and advise Joint Venture Board of Directors; develop project plan, monitoring and alert systems including financial reporting and accounting
- Supervise company's Phase I/II clinical trials at M.D. Anderson Cancer Center (Houston, Texas); Interface with investigators, study coordinators, CRO, regulatory submissions (FDA IND, annual reports, SAE reports), Data Monitoring Committee members, statistical analysis; liaison to potential strategic partners; supervise due diligence and inspection of clinical data

September 2004 – November 2007

VP, Business Development, Gamida Cell, Ltd.

- Initiate and manage several International and local alliances with academic and industrial partners (including drafting of confidentiality agreements, research agreements, and strategic partnerships with Big Pharma groups in US and EU)
- Manage and coordinate complex agreements and alliances with international partners (Amgen, J&J, Baxter) for value-creation as well as Freedom to Operate considerations; evaluate numerous in-license opportunities.
- Participate in international as well as local scientific and business conferences; attend numerous meetings with financial agents (VCs, Investment Banks, private investors); involved with funding negotiations, drafting financial projections, budget planning.
- Coordinate intellectual property activities and strategy
- Supervise PR and Media Planning activities
- Direct submission of grants and proposals for research and development funding

June 2003 – November 2007

OTHER ACTIVITIES

- Head of MBA program with focus on biomedical management, College of Management (Rishon Letziyon, Israel), July 2013 – Present
- Director (Member of Board of Directors), BioBlast Ltd., January 2012 – Present
- Member, Advisory Committee, Alon MedTech Ventures, April 2013 – Present
- Academic Director, MBA program with focus on biomedical management, College of Management (Rishon Letziyon, Israel), Fall 2009 – Spring 2011
- Reviewer in area of orphan disease therapies for the European Commission FP7 program, 2012
- Reviewer in the area of nanobiotechnology for the European Commission FP7 program, 2009
- Reviewer in the area of cell therapy for the European Commission FP7 program, Summer 2007
- Member of the American Society of Hematology (ASH), 2006-present
- Invited Lecturer (High-Schools) on Contemporary Issues in Biotechnology, 2002 – present
- President of Student Body and Student Council at Sackler Institute, 1996-1997

PUBLICATIONS

1. A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder. Manor I, Ben-Hayun R, Aharon-Peretz J, Salomy D, Weizman A, **Daniely Y**, Megiddo D, Newcorn JH, Biederman J, Adler LA. J Clin *Psychiatry*. 2012 Dec;73(12):1517-23.

2. Cohen YC, Scaradavou A, Stevens CE, Rubinstein P, Gluckman E, Rocha V, Horowitz MM, Eapen M, Nagler A, Shpall EJ, Laughlin MJ, **Daniely Y**, Pacheco D, Barishev R, Olmer L, Freedman LS. Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries. *Bone Marrow Transplant*. 2011 Jan;46(1):70-6. Epub 2010
May 3.

3. de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, Hosing C, Khouri I, Jones R, Champlin R, Karandish S, Sadeghi T, Peled T, Grynspan F, **Daniely Y**, Nagler A, Shpall EJ. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. *Bone Marrow Transplant*. 2008 May;41(9):771-8. Epub 2008 Jan 21.

4. Saxena A, Rorie CJ, Dimitrova D, **Daniely Y**, Borowiec JA. Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization. *Oncogene*. 2006 Nov 23;25(55):7274-88. Epub 2006 Jun 5.

5. **Daniely Y**, Liao G, Dixon D, Linnoila RI, Lori A, Randell SH, Oren M, Jetten AM. Critical role of p63 in the development of a normal esophageal and tracheobronchial epithelium. *Am J Physiol Cell Physiol*. 2004 Jul;287(1):C171-81.

6. Blander G, Zalle N, **Daniely Y**, Taplick J, Gray MD, Oren M. DNA damage-induced translocation of the Werner helicase is regulated by acetylation. *J Biol Chem*. 2002 Dec 27;277(52):50934-40. Epub 2002 Oct 15.

7. **Daniely Y**, Dimitrova DD, Borowiec JA. Stress-dependent nucleolin mobilization mediated by p53-nucleolin complex formation. *Mol Cell Biol*. 2002 Aug;22(16):6014-22.

8. **Daniely Y**, Borowiec JA. Formation of a complex between nucleolin and replication protein A after cell stress prevents initiation of DNA replication. *J Cell Biol*. 2000 May 15;149(4):799-810.

9. Iftode C, **Daniely Y**, Borowiec JA. Replication protein A (RPA): the eukaryotic
SSB. *Crit Rev Biochem Mol Biol*. 1999;34(3):141-80. Review.